Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

BACKGROUND: Papillary renal cell carcinoma (pRCC) is associated with EGFR expression and activation of MET signaling pathway. A randomized multicenter parallel two-stage phase II trial of MET inhibitor tivantinib alone or in combination with EGFR inhibitor erlotinib was conducted in patients with pR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Kidney Cancer
Main Authors: Twardowski, Przemyslaw W., Tangen, Catherine M., Wu, Xiwei, Plets, Melissa R., Plimack, Elizabeth R., Agarwal, Neeraj, Vogelzang, Nicholas J., Wang, Jinhui, Tao, Shu, Thompson, Ian M., Lara, Primo
Formato: Artigo
Idioma:Inglês
Publicado em: IOS Press 2017
Assuntos:
Research Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6179121/
https://ncbi.nlm.nih.gov/pubmed/30334014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/KCA-170018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados